SK Biopharm will participate in the 2026 BIO International Convention (BIO USA) to promote its global partnerships and artificial intelligence (AI)-based drug development strategies. The company plans to explore new collaboration opportunities and share its approach to utilizing AI across research and development (R&D).
The event will take place from June 22 to 25 at the San Diego Convention Center in the United States, as announced by SK Biopharm on June 16.
BIO USA, organized by the Biotechnology Innovation Organization, is the largest biotechnology event in the world. This year, over 20,000 industry professionals from 76 countries are expected to attend, sharing key industry trends and innovative technologies.
Following last year’s participation, SK Biopharm will again operate a standalone booth, located in the prominent Digital Health and AI Zone. During the event, the company will focus on seeking new collaboration opportunities through partnering meetings with global pharmaceutical and biotech companies and investors, while enhancing understanding of next-generation growth drivers.
The booth will feature the slogan "SK, AI for Every Patient," showcasing the comprehensive application of AI in drug discovery, digital transformation of R&D and operations, and patient-centered platforms.
SK Biopharm is expanding the application of its proprietary AI platform from research planning to candidate substance design and analysis, development strategy formulation, and operational optimization. The company aims to establish an AI system that supports real-time collaboration and decision-making, moving beyond simple analysis. This approach is expected to reduce trial and error and allow for a greater focus on high-value research.
"We will expand global cooperation and strengthen our competitiveness in AI-based drug development," said Lee Dong-hoon, CEO of SK Biopharm.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.